Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Fernandez Mercado, Marta ^a   Yip, Bon Ham ^a   Pellagatti, Andrea ^a   Davies, Carwyn ^a   Larrayoz, María José ^b   Kondo, Toshinori ^c   Pérez, Cristina ^d   Killick, Sally ^e   McDonald, Emma Jane ^e   Odero, María Dolores ^b,d   Agirre, Xabier ^d   Prósper, Felipe ^d   Calasanz, María José ^b   Wainscoat, James S ^a   Boultwood, Jacqueline ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NAVARRA   (Spain)

^c KAWASAKI MEDICAL SCHOOL   (Japan)

^d UNIVERSITY OF NAVARRA   (Spain)

^e ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; ASXL1 GENE; CBL GENE; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; DNMT3A GENE; FEMALE; FLT3 GENE; GENE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HUMAN; IDH1 GENE; IDH2 GENE; JAK2 GENE; KRAS GENE; MAJOR CLINICAL STUDY; MALE; MPL GENE; MUTATIONAL ANALYSIS; NPM1 GENE; NRAS GENE; NUCLEOTIDE SEQUENCE; RUNX1 GENE; SF3B1 GENE; TET2 GENE; TP53 GENE; WT1 GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYTOGENETIC ANALYSIS; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, NEOPLASM; HUMANS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROGNOSIS; YOUNG ADULT;

EID: 84865029087     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042334     Document Type: Article

References (23)

1. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD, ((2007)) Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 109:: 431--448.
2. Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, et al. ((2010)) Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 10:: 401.
3. Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, et al. ((2010)) Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 70:: 447--452.
4. Ishikawa Y, Kiyoi H, Tsujimura A, Miyawaki S, Miyazaki Y, et al. ((2009)) Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia. Eur J Haematol 83:: 90--98.
5. Abbas S, Rotmans G, Lowenberg B, Valk PJ, ((2008)) Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias. Haematologica 93:: 1595--1597.
6. Couronne L, Lippert E, Andrieux J, Kosmider O, Radford-Weiss I, et al. ((2010)) Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias. Leukemia 24:: 201--203.
7. Schlenk RF, Dohner K, Krauter J, Frohling S, Corbacioglu A, et al. ((2008)) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:: 1909--1918.
8. Carbuccia N, Trouplin V, Gelsi-Boyer V, Murati A, Rocquain J, et al. ((2010)) Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias. Leukemia 24:: 469--473.
9. Chou WC, Huang HH, Hou HA, Chen CY, Tang JL, et al. ((2010)) Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood 116:: 4086--4094.
10. Flach J, Dicker F, Schnittger S, Schindela S, Kohlmann A, et al. ((2011)) An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling. Leukemia 25:: 713--718.
11. Dicker F, Haferlach C, Sundermann J, Wendland N, Weiss T, et al. ((2010)) Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 24:: 1528--1532.
12. Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, et al. ((2011)) Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 118:: 5593--5603.
13. Thol F, Damm F, Ludeking A, Winschel C, Wagner K, et al. ((2011)) Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 29:: 2889--2896.
14. Beer PA, Delhommeau F, LeCouedic JP, Dawson MA, Chen E, et al. ((2010)) Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 115:: 2891--2900.
15. Pratcorona M, Abbas S, Sanders M, Koenders J, Kavelaars F, et al. ((2011)) Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value. Haematologica.
16. Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, et al. ((2011)) ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 118:: 6920--6929.
17. Jankowska AM, Makishima H, Tiu RV, Szpurka H, Huang Y, et al. ((2011)) Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood 118:: 3932--3941.
18. Boultwood J, Perry J, Pellagatti A, Fernandez-Mercado M, Fernandez-Santamaria C, et al. ((2010)) Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 24:: 1062--1065.
19. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, et al. ((2010)) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:: 553--567.
20. Metzeler KH, Maharry K, Radmacher MD, Mrozek K, Margeson D, et al. ((2011)) TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 29:: 1373--1381.
21. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, et al. ((2010)) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363:: 2424--2433.
22. Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, et al. ((2012)) Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia.
23. Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, et al. ((2012)) Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 30:: 742--750.